Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

136 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase I/II trial of dendritic cell-based active cellular immunotherapy with DCVAC/PCa in patients with rising PSA after primary prostatectomy or salvage radiotherapy for the treatment of prostate cancer.
Fucikova J, Podrazil M, Jarolim L, Bilkova P, Hensler M, Becht E, Gasova Z, Klouckova J, Kayserova J, Horvath R, Fialova A, Vavrova K, Sochorova K, Rozkova D, Spisek R, Bartunkova J. Fucikova J, et al. Among authors: becht e. Cancer Immunol Immunother. 2018 Jan;67(1):89-100. doi: 10.1007/s00262-017-2068-x. Epub 2017 Sep 25. Cancer Immunol Immunother. 2018. PMID: 28948333 Free PMC article. Clinical Trial.
Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer.
Podrazil M, Horvath R, Becht E, Rozkova D, Bilkova P, Sochorova K, Hromadkova H, Kayserova J, Vavrova K, Lastovicka J, Vrabcova P, Kubackova K, Gasova Z, Jarolim L, Babjuk M, Spisek R, Bartunkova J, Fucikova J. Podrazil M, et al. Among authors: becht e. Oncotarget. 2015 Jul 20;6(20):18192-205. doi: 10.18632/oncotarget.4145. Oncotarget. 2015. PMID: 26078335 Free PMC article. Clinical Trial.
Calreticulin exposure by malignant blasts correlates with robust anticancer immunity and improved clinical outcome in AML patients.
Fucikova J, Truxova I, Hensler M, Becht E, Kasikova L, Moserova I, Vosahlikova S, Klouckova J, Church SE, Cremer I, Kepp O, Kroemer G, Galluzzi L, Salek C, Spisek R. Fucikova J, et al. Among authors: becht e. Blood. 2016 Dec 29;128(26):3113-3124. doi: 10.1182/blood-2016-08-731737. Epub 2016 Nov 1. Blood. 2016. PMID: 27802968 Free PMC article.
Gene expression profiling of circulating tumor cells and peripheral blood mononuclear cells from breast cancer patients.
Hensler M, Vančurová I, Becht E, Palata O, Strnad P, Tesařová P, Čabiňaková M, Švec D, Kubista M, Bartůňková J, Špíšek R, Sojka L. Hensler M, et al. Among authors: becht e. Oncoimmunology. 2015 Dec 10;5(4):e1102827. doi: 10.1080/2162402X.2015.1102827. eCollection 2016 Apr. Oncoimmunology. 2015. PMID: 27141386 Free PMC article.
Calreticulin Expression in Human Non-Small Cell Lung Cancers Correlates with Increased Accumulation of Antitumor Immune Cells and Favorable Prognosis.
Fucikova J, Becht E, Iribarren K, Goc J, Remark R, Damotte D, Alifano M, Devi P, Biton J, Germain C, Lupo A, Fridman WH, Dieu-Nosjean MC, Kroemer G, Sautès-Fridman C, Cremer I. Fucikova J, et al. Among authors: becht e. Cancer Res. 2016 Apr 1;76(7):1746-56. doi: 10.1158/0008-5472.CAN-15-1142. Epub 2016 Feb 3. Cancer Res. 2016. PMID: 26842877
Shaping of an effective immune microenvironment to and by cancer cells.
Becht E, Goc J, Germain C, Giraldo NA, Dieu-Nosjean MC, Sautès-Fridman C, Fridman WH. Becht E, et al. Cancer Immunol Immunother. 2014 Oct;63(10):991-7. doi: 10.1007/s00262-014-1590-3. Epub 2014 Aug 12. Cancer Immunol Immunother. 2014. PMID: 25112529 Free PMC article. Review.
Cancer immune contexture and immunotherapy.
Becht E, Giraldo NA, Dieu-Nosjean MC, Sautès-Fridman C, Fridman WH. Becht E, et al. Curr Opin Immunol. 2016 Apr;39:7-13. doi: 10.1016/j.coi.2015.11.009. Epub 2015 Dec 17. Curr Opin Immunol. 2016. PMID: 26708937 Free article. Review.
Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells.
Goc J, Germain C, Vo-Bourgais TK, Lupo A, Klein C, Knockaert S, de Chaisemartin L, Ouakrim H, Becht E, Alifano M, Validire P, Remark R, Hammond SA, Cremer I, Damotte D, Fridman WH, Sautès-Fridman C, Dieu-Nosjean MC. Goc J, et al. Among authors: becht e. Cancer Res. 2014 Feb 1;74(3):705-15. doi: 10.1158/0008-5472.CAN-13-1342. Epub 2013 Dec 23. Cancer Res. 2014. PMID: 24366885
136 results